Quarterly report pursuant to Section 13 or 15(d)

Schedule of Accounts Payable (Details)

v3.24.3
Schedule of Accounts Payable (Details) - USD ($)
Sep. 30, 2024
Dec. 31, 2023
Sep. 30, 2023
Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]        
Other accounts payable $ 1,277,000 $ 683,000    
Total accounts payable 2,612,000 4,328,000    
Cytovance Biologics Inc [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Accounts payable to University of Minnesota 638,000 [1] 3,515,000 [1] $ 3,144,000 $ 2,283,000
Total accounts payable 810,000   $ 1,120,000  
2023 Warrants [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Accounts payable to University of Minnesota $ 697,000 $ 130,000    
[1] Accounts Payable to Cytovance Biologics, Inc. (“Cytovance”), a Related Party, since Cytovance owns greater than 5% of the Company’s issued and outstanding common stock